

PARKINSONNET GUIDELINES

PHYSIOTHERAPY

OCCUPATIONAL THERAPY

SPEECH AND LANGUAGE THERAPY

www.parkinsonnet.com/guidelines/

EUROPEAN REFERENCE NETWORKS
FOR RARE, LOW PREVALENCE AND COMPLEX DISEASES

Share. Care. Cure.



Disclaimer:

“The European Commission support for the production of this publication does not constitute endorsement of the contents which reflects the views only of the authors, and the Commission cannot be held responsible for any use which may be made of the information contained therein.”

More information on the European Union is available on the Internet (<http://europa.eu>).

Luxembourg: Publications Office of the European Union, 2019

© European Union, 2019

Reproduction is authorised provided the source is acknowledged.

THE EUROPEAN REFERENCE NETWORK FOR RARE NEUROLOGICAL DISEASES (ERN-RND)

ERN-RND is a European Reference Network established and approved by the European Union. ERN-RND is a healthcare infrastructure which focuses on rare neurological diseases (RND). The three main pillars of ERN-RND are (i) network of experts and expertise centres, (ii) generation, pooling and dissemination of RND knowledge, and (iii) implementation of e-health to allow the expertise to travel instead of patients and families.

ERN-RND unites 64 of Europe's leading expert centres as well as 4 affiliated partners in 24 Member States and includes highly active patient organizations. Centres are located in Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Slovenia, Spain and Sweden.

The following disease groups are covered by ERN-RND:

- Ataxias and Hereditary Spastic Paraplegias
- Atypical Parkinsonism and genetic Parkinson's Disease
- Dystonia, Paroxysmal Disorders and Neurodegeneration with Brain Ion Accumulation
- Frontotemporal Dementia
- Huntington's Disease and other Chorea
- Leukodystrophies

Specific information about the network, the expert centres and the diseases covered can be found at the network's web site www.ern-rnd.eu.

Affirmation of value:

The European Reference Network for Rare Neurological Diseases has affirmed the value of these guidelines.

Please note:

The following guidelines have been developed for Parkinsonism in general and not specifically for atypical parkinsonian disorders. For latter diseases, the evidence (particularly for Progressive Supranuclear Palsy, PSP, and Multiple System Atrophy, MSA) remains insufficient to draw final conclusions on the efficacy of the recommended interventions. However, based overlapping symptoms, it is reasonable to assume that the recommendations might apply to atypical Parkinsonism as well.

The guidelines have been developed in 2008 (speech and language therapy and occupational therapy) and 2014 (physiotherapy), therefore they might be incomplete in some cases, especially for speech and language therapy.

DISCLAIMER

Clinical practice guidelines, practice advisories, systematic reviews and other guidance published, endorsed or affirmed by ERN-RND are assessments of current scientific and clinical information provided as an educational service.

The information (1) should not be considered inclusive of all proper treatments, methods of care, or as a statement of the standard of care; (2) is not continually updated and may not reflect the most recent evidence (new information may emerge between the time information is developed and when it is published or read); (3) addresses only the question(s) specifically identified; (4) does not mandate any particular course of medical care; and (5) is not intended to substitute for the independent professional judgement of the treating provider, as the information does not account for individual variation among patients. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ERN-RND provided this information on an “as is” basis, and makes no warranty, expressed or implied, regarding the information. ERN-RND specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ERN-RND assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.

METHODS

The endorsement process has been performed by the Working Group for Neurorehabilitation of ERN-RND.

Consent on endorsement was given by the entire Working Group on: 12 July 2023

Working Group for Neurorehabilitation:

Working Group Coordinators:

Annemieke Buizer ²; Antonio Federico ⁷; Maria Judit Molnar ⁴⁸; Jorik Nonnekens ⁴⁹

Working Group Members:

Healthcare professionals:

Ditte Harboe Danielsen ¹; Laura Bonouvrié ²; David Crosiers ³; Patrick Cras ³; Angelo Antonini ⁴; Carmelo Chisari ⁵; Marianna Delussi ⁶; Domenico Plantone ⁷; Pauline Lallemand ⁸; Dagmar Timann-Braun ⁹; Elena Salvatore ¹⁰; Giovanna Lopane ¹¹; Bosco Méndez Ferrer ¹²; Dafin Muresanu ¹⁴; Letizia Leocani ¹⁴; Karin Diserens ¹⁵; Nina Petrpolou ¹⁶; Caterina Mariotti ¹⁷; Harro Seelaar ¹⁹; Alberto Albanese ²⁰; Roberto Gatti ²⁰; Jörg B Schulz ²¹; Lenka Krajčovičová ²²; Emanuela Pagliano ²³; Martin Srp ²⁴; Ruth Van Der Looven ²⁵; Christoph Gutenbrunner ²⁶; Ana Maria Dominguez Cobo ²⁷; Ariadna Riera Castello ²⁷; Julita Medina Cantillo ²⁷; Eva López Valdés ²⁸; Clara Casaco Blanco ²⁹; Andreea Mihaela Dumitrescu ²⁹; David Gómez-Andrés ³⁰; Mireia Alvarez ³⁰; Pedro Oliva Nacarino ³¹; Susana Chajma Izquierdo ³²; Lourdes López de Munain ³³; Jan Sielczak ³⁴; Iwona Sarzynska-Dlugosz ³⁴; Roberto Gatti ³⁵; Luigi Lavorgna ³⁶; Jürgen Andrich ³⁷; Natasa Klepac ³⁸; Philip Homburg ³⁹; Alena Zumrová ⁴⁰; Lucie Štovičková ⁴⁰; Ondřej Čakrt ⁴⁰; Gregor Wenning ⁴¹; Agius Anastasi Andrei ⁴²; Heli Helander ⁴³;

Elina Pucite ⁴⁴; Enrico Bertini ⁴⁵; Francesco Nicita ⁴⁵; Gessica Vasco ⁴⁵; Maurizio Petrarca ⁴⁵; Susanna Summa ⁴⁵; Anne Norup ⁴⁶; Mette Lindelof ⁴⁶; Samih Almudafar ⁴⁷; Alexander Geurts ⁴⁹; Gabriella Gardian ⁵⁰; Karen O'Connell ⁵¹; Kadri Medijainen ⁵²; Dimitris Sokratous ⁵³; Jiří Běhounek ⁵⁴; Thomas Klopstock ⁵⁵; Rebecca Schuele ⁵⁶; Kathrin Reetz ⁵⁷; Marcus Grobe-Einsler ⁵⁸; Kerstin Lüdtke ⁵⁹; Ludger Schöls ⁶⁰; Bernhard Landwehrmeyer ⁶¹; Thomas Musacchio ⁶²; Jadwiga Kubica ⁶³; Gudrun Schönherr ⁶⁴; Sylvia Boesch ⁶⁴; Wolfgang Nachbauer ⁶⁴; Agnes Elema ⁶⁵; Deborah Sival ⁶⁵; Marina de Koning-Tijssen ⁶⁵; Wieke Eggink ⁶⁵; Katja Groleger Srsen ⁶⁶; Ieva Michailovienė ⁶⁷; Rūta Kaladytė-Lokominienė ⁶⁷; Claudia Vinciguerra⁶⁸

Patient organisation representatives:

Mary Kearney ¹⁸; Monika Benson ¹⁸; Nataliya Grigorova ¹⁸

¹ Aarhus Universitetshospital; ² Amsterdam University Medical Center, the Netherlands; ³ Antwerp University Hospital; ⁴ AO di Padova; ⁵ AOU Pisana, Pisa; ⁶ AOU Policlinico Bari; ⁷ AOU Senese, Italy; ⁸ Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, France: Reference Centre for Rare Diseases 'Neurogenetics'; ⁹ Ataxia Networks; ¹⁰ Azienda Ospedaliera Universitaria Federico II, Napoli; ¹¹ Azienda USL di Bologna - IRCCS Istituto delle Scienze Neurologiche; ¹² Complejo Hospitalario Regional Virgen del Rocío, Sevilla; ¹⁴ EAN; ¹⁵ EFNR/WFNR; ¹⁶ Eginitio Hospital Athens, Greece; ¹⁷ EHDN; ¹⁸ ePAG; ¹⁹ Erasmus MC: University Medical Center Rotterdam, Netherlands; ²⁰ European Dystonia Network; ²¹ European FA network; ²² Fakultní nemocnice U Sv. Anny v Brně; ²³ Foundation IRCCS neurological institute Carlo Besta – Milan, Italy; ²⁴ General University Hospital in Prague, Czech Republic; ²⁵ Ghent University Hospital; ²⁶ Hannover Medical School; ²⁷ Hospital Clínic i Provincial de Barcelona y Hospital de Sant Joan de Déu, Spain; ²⁸ Hospital Clínico San Carlos, Madrid; ²⁹ Hospital General Universitario Gregorio Marañón, Madrid; ³⁰ Hospital Universitari Vall d'Hebron, Spain; ³¹ Hospital Universitario Central de Asturias, Oviedo; ³² Hospital Universitario La Paz, Madrid; ³³ Hospital Universitario Marqués de Valdecilla, Santander; ³⁴ Institute of Psychiatry and Neurology, Warsaw; ³⁵ IRCCS Clinical Institute Humanitas – Rozzano, Italy; ³⁶ Italian Society of Neurology; ³⁷ Katholisches Klinikum Bochum; ³⁸ Klinički bolnički centar Zagreb; ³⁹ Leiden University Medical Center; ⁴⁰ Motol University Hospital, Czech Republic; ⁴¹ MSA study group; ⁴² National Coordination Hub, Mater Dei Hospital (MDH), Malta; ⁴³ Oulu University Hospital; ⁴⁴ Pauls Stradins Clinical University Hospital, Riga Latvia; ⁴⁵ Pediatric hospital Bambino Gesù, Rome, Italy; ⁴⁶ Rigshospitalet, Copenhagen University Hospital; ⁴⁷ Sahlgrenska Universitetssjukhuset, Mölndal; ⁴⁸ Semmelweis University, Hungary; ⁴⁹ Stichting Katholieke Universiteit, doing business as Radboud University Medical Center Nijmegen, Netherlands; ⁵⁰ Szent-Györgyi Albert Medical Center, University of Szeged; ⁵¹ Tallaght University Hospital, Dublin; ⁵² Tartu University Hospital, Estonia; ⁵³ The Cyprus Foundation for Muscular Dystrophy Research (The Cyprus Institute of Neurology and Genetics); ⁵⁴ Thomayer University Hospital, Prague; ⁵⁵ TIRCON; ⁵⁶ Treat-HSP; ⁵⁷ University Hospital Aachen; ⁵⁸ University Hospital Bonn, Germany; ⁵⁹ University Hospital Schleswig-Holstein, Germany; ⁶⁰ University Hospital Tübingen, Germany; ⁶¹ University Hospital Ulm, Germany; ⁶² University Hospital Würzburg; ⁶³ University Hospital in Krakow, Poland; ⁶⁴ University Hospital Innsbruck, Tirol Kliniken GmbH; ⁶⁵ University Medical Center Groningen, Netherlands; ⁶⁶ University Medical Centre Ljubljana, Slovenia; ⁶⁷ Vilnius University Hospital Santaros Klinikos, Lithuania; ⁶⁸ AOU OO.RR. S.Giovanni di Dio e Ruggi d'Aragona

REFERENCES

1. Physiotherapy guideline:
<https://www.parkinsonnet.com/discipline/physiotherapy/>
2. Occupational therapy guideline:
<https://www.parkinsonnet.com/discipline/occupational-therapy/>
3. Speech and language therapy guideline:
<https://www.parkinsonnet.com/discipline/speech-and-language/>



European Reference Networks

<https://ec.europa.eu/health/ern>



European Reference Network
for rare or low prevalence complex diseases

Network
Neurological Diseases (ERN-RND)

Coordinator
Universitätsklinikum
Tübingen — Deutschland

www.ern-rnd.eu

Co-funded by the European Union

